In a 50-year-old woman with a history of a catheter-related venous thromboembolism (VTE) during chemotherapy for acute promyelocytic leukemia eight years ago, the safety of hormone replacement therapy (HRT) requires careful individualized assessment due to elevated thrombotic risk associated with both prior VTE and estrogen exposure.
Current UK clinical guidance classifies catheter-related thrombosis as a provoked VTE, typically associated with transient major risk factors such as central venous catheters and chemotherapy NICE NG158. After a significant lapse of eight years without recurrent VTE and in cancer remission, long-term anticoagulation is often not indicated NICE NG158. However, the presence of any prior VTE is generally considered a relative contraindication to estrogen-containing hormone therapy due to increased risk of thrombosis NICE NG158.
HRT, particularly estrogen-containing formulations, increase VTE risk by promoting a prothrombotic state, and this risk is further amplified in women over 50 or with a history of thrombosis LaVasseur et al. 2023. Recent large-scale evidence confirms that estrogen therapy increases venous thromboembolism risk significantly, especially in older patients LaVasseur et al. 2023. Thus, initiating HRT in a woman with prior VTE—even if provoked and remote—demands judicious risk-benefit evaluation.
In oncology, patients with venous thromboembolism related to chemotherapy and central catheters have elevated CAT (cancer-associated thrombosis) risk, but when cancer is in remission and risk factors are removed, VTE recurrence risk decreases NICE NG158,Poenou et al. 2026. Consequently, while current NICE guidelines do not outright forbid HRT in such cases, they recommend avoiding estrogen if possible and favouring non-hormonal or the lowest effective doses for symptom relief, preferably using oestrogen-only regimens if the uterus is absent NICE CG164.
Additional risk factors such as obesity or thrombophilia testing are relevant but less impactful more than several years after the event if none are identified NICE NG158. Alternative menopause symptom management strategies should be considered if there remain concerns about thrombosis risk NICE CG164. Shared decision-making with discussion of thrombosis risks, benefits of symptom control, and close monitoring is essential.
Summary: While not absolutely contraindicated, HRT with estrogen in a 50-year-old woman who had catheter-related thrombosis during chemotherapy eight years ago carries an increased risk of recurrent thrombosis. Use of HRT should only be considered after thorough assessment, minimising estrogen dose and duration, preferring oestrogen-only preparations if suitable, or alternative therapies. Careful counselling and close follow-up are recommended NICE NG158,NICE CG164,LaVasseur et al. 2023,Poenou et al. 2026.
Key References
- CKS - Pulmonary embolism
- CKS - Platelets - abnormal counts and cancer
- CKS - Deep vein thrombosis
- NG158 - Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
- CG164 - Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
- (LaVasseur et al., 2023): Estrogen-based hormonal therapy and the risk of thrombosis in COVID-19 patients.
- (Poenou et al., 2026): Venous Thromboembolism in Women with Breast and Gynaecological Cancers: What Do We Know and What Should We Do?
- (Hung et al., 2025): Association between iron deficiency anemia and risk of venous thromboembolism: a multi-institutional retrospective study.